Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.475
-0.005 (-0.34%)
Aug 10, 2026, 9:41 AM EDT - Market open
Geron Employees
Geron had 258 employees as of December 31, 2025. The number of employees increased by 29 or 12.66% compared to the previous year.
Employees
258
Change (1Y)
29
Growth (1Y)
12.66%
Revenue / Employee
$792,864
Profits / Employee
-$262,062
Market Cap
947.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 258 | 29 | 12.66% | 258 | 0 |
| Dec 31, 2024 | 229 | 88 | 62.41% | 229 | 0 |
| Dec 31, 2023 | 141 | 34 | 31.78% | 141 | 0 |
| Dec 31, 2022 | 107 | 35 | 48.61% | 107 | 0 |
| Dec 31, 2021 | 72 | 17 | 30.91% | 69 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Replimune Group | 465 |
| Omeros | 175 |
| Aura Biosciences | 113 |
| Janux Therapeutics | 108 |
| Odyssey Therapeutics | 100 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
GERN News
- 5 days ago - Geron Earnings Call Transcript: Q2 2026 - Transcripts
- 5 days ago - Geron Earnings release: Q2 2026 - Filings
- 5 days ago - Geron Quarterly report: Q2 2026 - Filings
- 5 days ago - Geron reports Q2 EPS (2c), consensus (1c) - TheFly
- 5 days ago - Geron sees FY26 revenue $220M-$240M, consensus $234.22M - TheFly
- 5 days ago - Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 8 days ago - Geron Slides: Corporate presentation - Filings
- 18 days ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire